Bio-Thera Out-Licenses Golimumab To Russia And CIS

Represents Foray Into ‘Important Market’

 
• By Dean Rudge

With a number of next wave candidates in its pipeline, China’s Bio-Thera Solutions has licensed one of them, golimumab, to Russian player Pharmapark, ahead of a global Phase III trial later this year.

Russia_Night
Pharmapark will leverage its strong local presence, sales and marketing capabilities, Bio-Thera said • Source: Shutterstock

More from Biosimilars

More from Products